Lupin Settles US Patent Dispute With Astellas for $90 Million, Secures Mirabegron Sales

Indian pharmaceutical company Lupin has reached a $90 million settlement with Japan-based Astellas Pharma in a patent dispute related to the bladder disorder drug Mirabegron. This agreement resolves the ongoing legal case and allows Lupin to continue selling the medicine in the United States.

Under the deal, Lupin and its US subsidiary will pay $75 million upfront and additional per-unit licensing fees on Mirabegron sales until September 2027.

Background of the Dispute

The conflict began after Lupin launched a generic version of Myrbetriq, Astellas’ treatment for overactive bladder. A US court decision had created uncertainty about whether generic versions could remain in the market, leading to the legal battle between the companies.

Astellas confirmed that the settlement ends the litigation and said it is reviewing the possible financial impact for the fiscal year ending March 31, 2026.

Read More: RailTel Secures ₹94.23 Crore Order from Modern Coach Factory; Shares Rise Over 2%!

Lupin Share Price Movement

Lupin share price (NSE: LUPIN) was trading at ₹2,215.70 on February 10 at 12:13 pm IST, up ₹18.90 or 0.86% for the day. The stock opened at ₹2,214.00, reached an intraday high of ₹2,233.80, and touched a low of ₹2,204.60. The company’s market capitalisation stood at around ₹1.01 lakh crore, with a P/E ratio of 23.46. Over the past year, the stock has moved between a 52-week high of ₹2,244.50 and a 52-week low of ₹1,795.20. Lupin offers a dividend yield of 0.54%, with a quarterly dividend of ₹2.99 per share.

Conclusion

Lupin’s $90 million settlement with Astellas brings clarity to its US Mirabegron sales and reduces legal risks. The agreement could support stable revenue in the near term and provide a temporary competitive advantage in the generic drug market.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.